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Background: Sarcoidosis is a multi-systemic inflammatory disorder, which affects the lungs
in 90% of the cases. The main pathologic feature is chronic inflammation resulting in non-
caseating granuloma formation. Until now there is no satisfying biomarker for diagnosis or
prognosis of sarcoidosis. This study is focused on the detection of potential biomarkers in
serum for the diagnosis of sarcoidosis using surface-enhanced laser desorption ionization-
time of flight-mass spectrometry (SELDI-TOF-MS).
Methods: For detection of potential biomarkers, protein profiles of anion exchange
fractionated serum of 35 sarcoidosis patients and 35 healthy controls were compared using
SELDI-TOF-MS. Sensitivities and specificities of the potential biomarkers obtained with
SELDI-TOF-MS, generated with decision tree algorithm, were compared to the conven-
tional markers angiotensin converting enzyme (ACE) and soluble interleukin-2 receptor
(sIL-2R).
Results: Optimal classification was achieved with metal affinity binding arrays. A single
marker with a mass-to-charge (m/z) value of 11,955 resulted in a sensitivity and specificity
of 86% and 63%, respectively. A multimarker approach of two peaks, m/z values of 11,734
and 17,377, resulted in a sensitivity and specificity of 74% and 71%, respectively. These
sensitivities and specificities were higher compared to measurements of ACE and sIL-2R.
Identification of the peak at m/z 17,377 resulted in the a-2chain of haptoglobin.Elsevier Ltd. All rights reserved.
387 49 77; fax:+31 43 387 46 92.
.azm.nl (W.K. Wodzig).
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J.A. Bons et al.1688Conclusions: This study acts as a proof-of-principle for the use of SELDI-TOF-MS in the
detection of new biomarkers for sarcoidosis. The peak of the multimarker at m/z 17,377
was identified as the a-2chain of haptoglobin.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Sarcoidosis is a systemic granulomatous disorder of unknown
cause characterised by its pathological hallmark, the
noncaseating granuloma.1,2 The clinical presentation of
sarcoidosis is highly variable.3 Involvement of the lungs or
intrathoracic lymph nodes becomes clinically evident in 90%
of the symptomatic patients during their disease and up to
30% show spontaneous remission.4 A chronic course occurs in
10–30% of the patients, at times resulting in significant
impairment of lung function.5,6 Unfortunately, till now there
is no good marker for both diagnosis and prognosis of
sarcoidosis.
It is obvious that there is a great need to discover novel
biomarkers for sarcoidosis and translate them to routine
clinical use,7 where they can play an important role in both
diagnosis and follow-up. Proteomics analysis has been
successfully employed in the discovery of new biomarkers
in different human diseases.8 Surface-enhanced laser
desorption ionization-time of flight-mass spectrometry
(SELDI-TOF-MS) is a promising new technology in the search
for new biomarkers and was first introduced by Hutchens
and Yip.9 The ProteinChip system manufactured by Cipher-
gen Biosystem Inc. indicated as SELDI-TOF-MS has the
potential to discover useful biomarkers faster than any
existing technology. Because of the multifactorial nature of
sarcoidosis, it is very likely that a combination of several
markers will be necessary to effectively detect and diagnose
sarcoidosis. Since the study of Petricoin et al.10 on protein
profiling to detect ovarian cancer, the use of SELDI protein
profiling as a diagnostic tool, has become an important
subject of investigation.11 Until now this approach has been
suggested for different diseases, for example ovarian10,12–16
prostate17–21 and lung22 cancer research, but also inflam-
matory diseases.23,24 Recently, Kriegova et al.25 reported
protein profiles of bronchoalveolar lavage fluid (BALF) from
patients with pulmonary sarcoidosis using SELDI-TOF-MS.
Furthermore, these protein patterns in sarcoid BALF were
linked to particular disease course, i.e. stages of sarcoidosis.
Sarcoidosis markers were also detected with a two-dimen-
sional gelelectrophoresis (2-DE) approach in BALF26,27 and
serum.28 The group of Song et al.29 collected sarcoidosis
tissue to detect sarcoidosis markers using a protein
immunoblot assay. This is the first study that detected
markers in serum using SELDI-TOF-MS.
The aim of this study is focused on the detection of
potential serum biomarkers for the diagnosis of sarcoidosis
using SELDI-TOF-MS. In this study, the sensitivity and
specificity obtained with the SELDI-TOF-MS technique will
be compared with the sensitivities and specificities of the
ACE activity and sIL-2R concentration measurements,because these two blood markers are often used in the
assessment and the follow-up of sarcoidosis.30–32Materials and methods
Patients and samples
Sarcoidosis patients who visited a education meeting held at
the University Hospital Maastricht February the 24th 2005
were asked to participate. Of the 120 attendees, 100 agreed
to participated. The diagnosis sarcoidosis was based on
consistent clinical features and BAL fluid analysis results,
according to the WASOG guidelines33 with a biopsy confirm-
ing sarcoidosis in 80% of cases. A healthy control group
consisted of partners of the patients and employees of the
hospital without any relevant medical history. Finally, out
these 100 sarcoidosis patients 35 cases were enrolled who
met the following inclusion criteria: a time since diagnosis of
less than 10 years (12 patients with a time since diagnosis
longer than 10 years were excluded from the study), non-
smoker (18 patients which were smokers at the moment of
blood collection were excluded from the study), using no
medication and not suffering from other diseases (31
patients which used corticosteroids at the moment of blood
collection and 25 patients who suffered from other diseases,
like diabetes, heart failure, which were not related to
sarcoidosis, were excluded from the study). Out of the
healthy control also 35 persons were selected matched for
sex and age. The Medical Ethical Committee of the Hospital
approved the procedure followed. Informed consent was
obtained from all participants.
Characteristics of the studied population are illustrated in
Table 1. Collection of serum samples was standardized by
using a clotting time of 30min at room temperature,
spinning for 15min at a speed of 4000 RPM (3000g) and
storage of the samples in aliquots within 1 h at 80 1C after
blood collection.34 All fractionated serum samples had
only 2 thaw steps from collection to analyzing.
Serum ACE activity was measured by colorimetric method
(Cat. nr. FU 116; Fujirebio Inc.) and soluble IL-2R (sIL-2R)
was determined by a two-site chemiluminescent enzyme
immunometric assay (Cat. nr. LKIP1; Diagnostic Product
Corporation) on the IMMULITE Automated Analyzer. Serum
was also used for analyses of the possible biomarker
haptoglobin detected during this study. Total haptoglobin
was measured by particle-enhanced immunonephelometry
on the BN Prospec (Dade Behring).
Lung function indices, including the forced expiratory
volume in 1 s (FEV1) and forced vital capacity (FVC), were
measured with a pneumotachograph. The diffusing capacity
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Table 1 Clinical characteristics of the studied population.
Sarcoidosis patients Healthy controls
N 35 35
Gender, M/F 18/17 16/19
Age, years 45.678.8 47.379.8
Biopsy, n, (%) 27 (77.1%)
Time since diagnosis, years, (mean) 1–9 (5)
Serological markersy
sIL-2R, U/mL 632.0 (437.5–859.5) 506.0 (394.0–597.5)





Chest radiographic stage, n
Stage 0/I/II/III/IV 3/9/15/8/0
ACE, angiotensin converting enzyme; DLCO, diffusing capacity for carbon monoxide; FEV1, forced expiratory volume in 1 s; FVC, forced
vital capacity; sIL-2R, soluble interleukin-2 receptor.
Variables presented as mean7SD, as they follow a Gaussian distribution.
ySerological markers are presented as median with range (25th–75th percentiles) within parentheses.
Biomarkers for sarcoidosis 1689for carbon monoxide (DLCO) was measured by the single-
breath method. Both measurements were performed on a
Masterlab (Jaeger, Wu¨rzburg, Germany). Values were ex-
pressed as a percentage of those predicted.35 Chest radio-
graphs were graded according to the radiographic staging of
DeRemee (0–III), with stage IV, the end stage of lung fibrosis,
added.36,37 Both the radiographic staging and pneumotacho-
graphy tests were performed and interpreted by two
professionals who were blinded to the patient’s histories.
Statistical analysis
Statistical analysis was performed with SPSS 11.0 for
Windows (SPSS). ROC curve analyses38 were performed for
the ACE activity and sIL-2R concentrations. The optimal cut-
off point coincides with the point on the ROC curve where
the sum of sensitivity and specificity is maximal. When there
were more cut-off points with the same sum, the one with
the highest sensitivity was chosen. At this point the slope to
the ROC curve equals unity, which is under certain
conditions the result of minimization of the total costs
attributable to false-positive and false negative outcomes.
Groups comparisons were performed by means of para-
metric tests (Independent Samples t-test). A two-sided p-
value of less than 0.05 was considered to be statistically
significant.
SELDI analysis
An anion exchange procedure was used, which allowed high-
throughput fractionation of serum based on the biophysical
properties of proteins.39 Serum was separated into six
different fractions (pH9+flow through, pH7, pH5, pH4,
pH3, and organic wash). The anion exchange fractionation
was standardized according to the Ciphergen protocols.For the anion exchange fractionation, we used 20 ml serum
and 30 ml (9 M urea, 2%Chaps, 50mM Tris-HCL pH9) as
starting material according to the Ciphergen protocols.
Linke et al.40 illustrated that fractionation greatly increases
the number of peptide and protein ion signals, when
compared to both unfractionated as well as albumin-
depleted samples and this will increase the chance to find
potential biomarkers.
In the screening experiment, each fraction of 8 sarcoi-
dosis and 8 healthy controls was applied to three different
array surfaces (Ciphergen Biosystems Inc.) to find out the
optimal array and fraction. The weak cation exchange
(CM10), the immobilized metal affinity capture coupled with
copper (IMAC-Cu2+) and normal phase (NP20) arrays were
used.
For ProteinChip array binding, the spots on the IMAC
arrays were preloaded with 50 ml CuSO4 (0.1M). The CM10
and IMAC arrays were equilibrated twice with 100 ml of
binding buffer (Na-phosphate buffer 50mM, 0.5M NaCl
(pH7) for the IMAC arrays and Na-acetate (pH4) for the
CM10 arrays). Ten microliter of each fraction was diluted in
90 ml of the specific binding buffer as suggested by Ciphergen
and added to each well of the bioprocessor and mixed for
45min. After removing the remaining sample, the CM10 and
IMAC arrays were washed and mixed three times with 150 ml
binding buffer for 5min followed by one brief wash with
200 ml Hepes buffer (pH7). For the NP20 ProteinChip arrays,
the fractions were diluted with Milli-Q (1:1 v/v) and added
directly on each spot. The arrays were incubated in a humid
chamber for 30min, followed by a brief water rinse. All
steps were performed at room temperature.
The sinapinic acid solution (SPA) as energy absorbing
matrix was prepared according to the recommendations
of the manufacturer, with the exception that trifluoroacetic
anhydride (TFAH) as a solvent component was used
instead of trifluoroacetic acid (TFA). After all the arrays
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J.A. Bons et al.1690were dried, 1 ml SPA solution was applied. The spotting of
SPA was repeated once and the ProteinChip arrays
were stored at room temperature in the dark until
further use.
The CM10, IMAC and NP-20 arrays were read on a Protein
Biosystem IIc (PBS IIc) instrument. External calibration of
the instrument was performed using the All-in-1 peptide and
the All-in-1 protein molecular mass standards (Ciphergen
Biosystems) on the NP-20 array. A well-defined protocol for
calibration of the PBS IIc, implementation of quality control
(QC) samples and acceptance criteria for QC was used
in this study which was described in a previous study of
Bons et al.34Data analysis
For the detection of sarcoidosis biomarkers, serum protein
profiles of sarcoidosis patients and healthy controls were
compared. Peaks were auto detected using Ciphergen
Express Data manager 3.0.6 (Ciphergen Biosystems, Inc.).
The biomarker wizard clusters were exported to Biomarker
Patterns (BPS) 5.0.2 (Ciphergen Biosystems Inc.). BPS uses
the peak information generated by the training set of known
samples to build a binary decision tree algorithm. The
algorithm functions by assigning each sample in the data set
into 1 of the 2 groups or nodes with a rule based on the
intensity of a particular peak or splitter. Each sub node has a
different rule that further divides the data set and this
process continues until all cases are assigned into terminal
nodes. This results in correct classification percentages of
the so-called ‘‘learn set.’’ The software generates and tests
the models, using a process of cross-validation by randomly
picking 10% of the samples. The peaks that formed the main
splitters of the tree with the highest prediction rates in the
cross-validation analysis were then selected to make a final
decision tree with the greatest possible predictive power
and this results in correct classification percentages of the
so called ‘‘test set.’’ So the classification ability of the
decision tree algorithms in the learning set to distinguish
between sarcoidosis and controls was validated after cross-
validation, which results in a test set.
A Bayesian approach was used to calculate the expected
probabilities of each class in each terminal node. Sensitivity
was calculated as the ratio of the number of correctly
classified disease samples to the total number of disease
samples. Specificity was calculated as the ratio of the
number of control samples correctly classified to the total
number of control samples.41Identification
Sodium dodecyl sulphate–polyacrylamide gel
electrophoresis (SDS–PAGE) and two-dimensional
polyacrylamide gel electrophoresis (2-DE)
Twenty microliter of samples in which the peaks of the 3
biomarkers were present, but also samples in which the
peaks of the 3 biomarkers were absent, were loaded on
12.5% SDS–PAGE gels. For the 2-DE, 40 ml of the same
samples used for the SDS-PAGE were loaded for the first
dimension. The SDS-PAGE, 2-DE and the digestion procedurewere performed as described in the studies of Bouwman
et al.42,43 with minor modifications.
MALDI-TOF-MS
For matrix assisted laser desorption ionization-time of flight-
mass spectrometry (MALDI-TOF-MS), 1.5 ml of each peptide
mixture and 0.5 ml matrix solution (2.5mg/ml CHCA in 50%
acetonitrile/0.1% trifluoroacetic acid (TFA)) were spotted
automatically onto a 96-well-format target plate. The spots
were allowed to air dry for homogeneous crystallization.
Spectra were obtained using a M@LDI-LR mass spectrometer
(Waters). The instrument was operated in positive reflector
mode.
The peptide mass list was searched with ProteinLynx
Global Server v2.0 (Waters) or Mascot search engine against
the Swiss-Prot database. One miss-cleavage was tolerated,
carbamidomethylation was set as a fixed modification and
oxidation of methionine as an optional modification. The
peptide mass tolerance was set to 100 ppm. No restrictions
were made on the protein Mr and the pI. A protein was
regarded as identified when it had a significant ProteinLynx
or Mascot probability score (po0.05), a minimum of four
peptides were required to match.
Results
Serological markers
The ROC curve analysis of the patient and control groups for
the ACE and sIL-2R measurements are presented in Table 2.
For both measurements, the areas under the curves (AUCs)
were significantly different from the null hypothesis, true
area ¼ 0.5. For ACE the sensitivity and specificity percen-
tages were 70.6 and 71.4, respectively. For sIL-2R the
sensitivity and specificity percentages were 62.9 and 57.1,
respectively.
SELDI analysis
For choosing the optimal fraction and array, the number of
significant m/z values and the cluster plots were evaluated
for each condition with the Ciphergen Express software. For
single charged molecules, the m/z value is equal to the
molecular weight (MW) in dalton (Da). The cluster plots
illustrate the distribution of the intensities for each m/z
value. With an increased number of significant m/z values
(po0.05) and superior cluster plots, the chance to detect a
potential biomarker in a larger sample set is theoretically
higher. A cluster plot is superior when there is minor or no
overlap between the data points of the sarcoidosis patients
compared to the control samples, which means that there is
a good discrimination between both groups. By comparing
the different chips and fractions in the screening experi-
ments with 8 sarcoidosis patients and 8 healthy control
samples, we detected the most significant m/z values
(po0.05) with superior cluster plots in fraction 3 (n ¼ 5)
and 4 (n ¼ 7) on the IMAC array, these two conditions were
used for performing the IMAC experiment with 35 sarcoidosis
and 35 control samples.
By repeating the IMAC experiment with 35 sarcoidosis and
35 control samples, fraction 4 on the IMAC array resulted
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Table 2 ROC curve analysis results for the inflammatory markers, ACE and sIL-2R.
AUC (95% confidence intervals) Selected cut-off Sensitivity (%) Specificity (%)
ACE 0.779 (0.668–0.891) 16.5 70.6 71.4
sIL-2R 0.667 (0.539–0.795) 515.5 62.9 57.1
ACE, angiotensin converting enzyme; AUC, area under curve; sIL-2R, soluble interleukin-2 receptor.
Table 3 The m/z values of the peak splitters, the cut-off values of the peak intensities, the p-values and the results of the
learn and test set for the sarcoidosis and control samples per laser setting.






of the learn set
Correct classification
of the test set
LI 220 11,955 1.113 0.003 S: 30/35 ¼ 86% S: 30/35 ¼ 86%
SE 7 C: 23/35 ¼ 66% C: 22/35 ¼ 63%
LI 190 11,734 3.060 0.01 S: 26/35 ¼ 74% S: 26/35 ¼ 74%
SE 7 17,377 0.450 0.05 C: 29/35 ¼ 83% C: 25/35 ¼ 71%
The spectra were calibrated with the protein low calibration on the NP-20 array.
LI, laser intensity; m/z, mass-to-charge ratio; SE, detector sensitivity; S, sarcoidosis; C, control.
Biomarkers for sarcoidosis 1691in 2 significant m/z values (po0.05) and fraction 3 on the
IMAC arrays resulted in 7 significant (po0.05)m/z values. By
using Biomarkers Patterns, decision trees were made and
the decision trees generated from the fraction 3 samples
resulted in a superior classification of the sarcoidosis and
control samples, compared to the results from fraction
4 samples on the IMAC array.
For analysis of fraction 3 samples on the IMAC array, the
following settings were chosen: laser intensity 220 and
detector sensitivity 7. Biomarker Patterns generated a
decision tree using 1 splitter with a m/z value of 11,955
and a cut-off value of 1.113 which classified cases in 2
terminal nodes. The peak was upregulated in the samples of
sarcoidosis patients. The control terminal node contained 28
samples (23 control and 5 sarcoidosis samples) and the
sarcoidosis terminal node contained 42 samples (30 sarcoi-
dosis and 12 control samples). This single marker could
correctly classify 30 of 35 (86%) sarcoidosis patients and 23
of 35 (66%) controls in the training set. The ability of the
decision tree algorithms to distinguish between sarcoidosis
and controls was validated after cross-validation, which is
called the test set. In the test set, 30 of 35 (86%) samples
were correctly classified as sarcoidosis and 22 of 35 (63%)
samples were correctly classified as controls (Table 3).With a
lower laser intensity setting; laser intensity 190 and
detector sensitivity 7, Biomarkers Patterns generated a
decisions tree using 2 splitters withm/z values of 11,734 and
17,377 and cut-off values of 3.060 and 0.45, respectively
which classified patients and controls in 3 terminal nodes.
The peak with a m/z value of 11,734 was upregulated and
the peak with a m/z value of 17,377 was downregulated in
the sarcoidosis patient samples. The first control terminal
node which was based on the first splitter contained 21
samples (17 control and 4 sarcoidosis samples). The other 49
samples were divided in a sarcoidosis and control terminal
node using the second splitter. The sarcoidosis terminal nodecontained 32 samples (26 sarcoidosis and 6 control samples)
and the control terminal node contained 17 samples (12
control and 5 sarcoidosis samples). In the training set, 26 of
35 (74%) sarcoidosis and 29 of 35 (83%) controls were
correctly classified and in the test set, 26 of 35 (74%)
samples were correctly classified as sarcoidosis and 25 of 35
(71%) samples were correctly classified as controls (Table 3).
The SELDI-TOF-MS gel views of the 3 potential biomarkers
are indicated in Fig. 1. There is a variation in protein
expression between patients and controls. This is seen in the
cluster plots of the 3 m/z peak splitters used in the
Biomarker Patterns analysis (Fig. 2).Identification
SDS-PAGE and 2-DE were used for isolation and purification
of the potential biomarkers and MALDI-TOF-MS was used for
identification. We only tried to identify the three most
discriminating markers described in our study. For the
biomarker with a m/z value of 17,377 a sarcoidosis and a
healthy control sample were applied on a SDS-PAGE gel. In
Fig. 3, it is illustrated that the band at a molecular weight
(MW) of 17 kDa, which represents the peak at m/z 17,377, is
not visible in the sarcoidosis patient sample (A), but clearly
visible in the healthy control sample (B). This also indicates
that this peak is downregulated in the sarcoidosis patient
versus the healthy control. This agrees with the SELDI-TOF-
MS results. Identification of the 17 kDa peak, after excising
this peak out of the SDS–PAGE gel revealed the following
protein as the best candidate of database searches: a-chain
of haptoglobin (P00738) with a probability Mascot score
(probability based mowse score) of 86. Protein scores
greater than 67 are significant (po0.05). In the 2-DE gels
was seen that there were more spots around the MW of
17 kDa for the healthy control sample (Fig. 4), but
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Fig. 1 SELDI-TOF-MS gel views of the three potential biomar-
kers with m/z values of 11,955 (a), 11,734 (b), and 17,377 (c).
Representative protein spectra of three sarcoidosis (s) and
three control (c) samples are illustrated per marker. The marker
is indicated with a vector. The mass is given as m/z values on
the x-axis and the intensity is displayed along the y-axis.
Fig. 2 The cluster plots of the resulted peak splitters after
Biomarker Patterns analysis; m/z 11,955 (a), m/z 11,734 (b),
m/z 17,377 (c). The groups are indicated on the x-axis and the
normalized intensities are indicated on the y-axis. The
horizontal bars present the mean intensities for the control
and the sarcoidosis group.
J.A. Bons et al.1692unfortunately in this study we were unable to identify
the excised spots from the 2-DE gels. For the biomarkers
with a m/z value of 11,734 and 11,955, also a sarcoi-
dosis and control sample were applied on the SDS-PAGE gel,
but it was also not possible to identify the bands or spots
with MW around 11 kDa which represent the peaks at m/z
11,734 and 11,955 on either the SDS–PAGE gels or the 2-DE
gels.
In Fig. 3a and b there are also two bands visible around
15 kDa. These peaks are not the potential biomarkers with
m/z values 11,734 and 11,955. The peaks corresponding to
the bands at 15 kDa gave no significant difference between
sarcoidosis and control and were also not used for the
Biomarker Patterns tree algorithm. Excising these peaks out
of the SDS–PAGE revealed the following protein as the bestcandidate of database searches: Hemoglobin b subunit
(P68871) with a Mascot score (probability-based mowse
score) of 100.Total haptoglobin measurement
Because the peak of the multimarker at m/z 17,377 was
identified as the a-chain of haptoglobin, the total haptoglo-
bin was measured. The means and standard deviations (SD)
for the haptoglobin concentration (g/l) were 1.3270.48 for
the sarcoidosis group and 1.3170.43 for the healthy control
group. There was no significant difference in total hapto-
globin concentration between the sarcoidosis and healthy
control group (p ¼ 0.9).
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Fig. 3 Silver stained band pattern of one fraction 3 sarcoidosis
sample (a) and one fraction 3 healthy control sample (b)
separated by SDS-PAGE. The left lane shows the marker and the
right lane shows the sarcoidosis sample (S70) in Fig. 3a and the
healthy control sample (K1) in Fig. 3b. In Fig. 3a there is no
band visible at MW 17 kDa. Fig. 3b clearly shows a band at
17 kDa and this band is indicated with a vector.
Fig. 4 Silver stained spot pattern of one fraction 3 sarcoidosis
sample (a) and one fraction 3 healthy control sample (b)
separated by 2-DE. In both 2-DE gels Apo A1 was identified with
a MW of 25 kDa. Fig. 4b clearly shows that below the Apo A1
spot, there are 4 protein spots around a MW of 17 kDa with
different pI values in the 2-DE gel. These protein spots are not
visible in Fig. 4a.
Biomarkers for sarcoidosis 1693Discussion
This is the first study that shows that protein profiling in
serum using SELDI-TOF-MS can be used as a diagnostic tool
for sarcoidosis. It was demonstrated that the diagnostic
value of the biomarkers obtained with SELDI-TOF-MS
appeared to be favorable compared to the diagnostic value
of ACE and sIL-2R in the same study population. At present,
there still is no appropriate parameter to assess the activity
of sarcoidosis. Clinical activity is assessed based on onset,
worsening or persistence of symptoms, or signs directly
related to sarcoidosis and a combination of clinical para-
meters.33
Despite its shortcoming, ACE is mostly used in the
assessment and the follow-up of sarcoidosis.31 Recently
some studies reported that sIL-2R appeared to be a better
marker to predict disease severity compared to the
traditionally used ACE, but there is a great overlap in the
sensitivity and specificity results of both serum mar-
kers.30,32,44 Although both ACE and sIL-2R are used in the
assessment and the follow-up of sarcoidosis, they still
appeared to be inferior to the SELDI-TOF-MS data in our
study.
The present study demonstrated that there appeared to
be a great variety in the protein patterns between patients,
but also within controls. This variation is caused by the
biological variation and analytical variation of SELDI-TOF-
MS.34 Potential sources of variability that arise during SELDI-
TOF-MS profiling include spot-to-spot variation of chip
surfaces, laser detector variability over time, pipetting
variability45 and the crystallization process of the energy-
absorbing matrix.46,47 But in spite of this variation in
intensities and biological variability, we were able to findpotential biomarkers with the Biomarker Patterns software.
A sensitivity of 86% and a specificity of 63% was reached with
a single marker with a m/z value of 11,955 (upregulated in
sarcoidosis versus control) and a sensitivity of 74% and a
specificity of 71% was reached with a multimarker using two
peaks with m/z values 11,734 (upregulated in sarcoidosis
versus control) and 17,377 (downregulated in sarcoidosis
versus control). We only tried to identify the three most
discriminating markers described in our study. The other m/
z peaks were not identified. Using Mascot search engine
against the Swiss-Prot database we found that the peak at
17 kDa excised from the SDS–PAGE gel was the a-chain of
haptoglobin. Haptoglobin consists of two different polypep-
tide chains, the a-chain and the b-chain and these are linked
by disulfide bonds. Three Haptoglobin phenotypes, Hpt 1–1
(structural formula: (a1b)2)), Hpt 2–1 (structural formula:
[(a1b)2+(a
2b)n]) and Hpt 2–2 (structural formula: (a
2b)n , are
genetically determined by a polymorphism with two alleles:
Hpt-1 and Hpt-2. This polymorphism results in variants in a-
chains: a1 (8.9 kDa) and a2 (16 kDa). The a1 is monomeric and
the a2 is partially dimeric (probably the result of incomplete
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J.A. Bons et al.1694genetic crossover. The b-chain (40 kDa) is heavier than the a-
chain and is identical in all haptoglobin phenotypes.48 The
marker at 17 kDa which was detected in our study is
compatible with the a-2 chain of haptoglobin.
It is known that in the presence of oxidative stress,
glucose-6-phosphate dehydrogenase (G6PD) deficiency
leads to hemolysis,49 which causes a decrease in haptoglo-
bin, which as such might clarify the lower haptoglobin
fragment peaks in sarcoidosis patients. Therefore, total
haptoglobin of the sarcoidosis and healthy control
serum samples were compared. There was no significant
difference between both groups. This can be caused due to
the fact that the 17 kDa peak is only the a-2 chain of
haptoglobin and the total haptoglobin assay measures the
total haptoglobin complex. Therefore, specific antibodies
against the a-chain of haptoglobin should be used to
compare both groups.
Another explanation might be the fact that the 17 kDa
peak is not a single marker, but it is part of a multimarker.
The 2-DE gel of the healthy control also clearly shows that
there are 4 protein spots around a MW of 17 kDa with
different pI values in the 2-DE gel. These spots are not
visible in the 2-DE gel of the sarcoidosis samples This
indicates that there are more proteins with the same MW,
but these proteins have another pI value.
Recently, Kriegova et al.25 compared protein profiles
from sarcoidosis patients with healthy controls in bronch-
oalveolar lavage fuid (BALF). In line with our findings, they
found a peak with a MW of 11.7 kDa upregulated in
sarcoidosis versus controls. However, no further analyzing
or identifying of this sarcoidosis-associated peak was
performed. Because the calibration procedure is not
described in the study of Kriegova et al., we are not
absolutely sure if we detected the same peak. However,
in most SELDI-TOF-MS studies, the All-in-1 peptide and the
All-in-1 protein molecular mass standards (Ciphergen
Biosystems) are used for the external calibration, like in
our study.
In the present study serum was used for the protein
profiling experiments, because collection of blood is much
less invasive compared to collection of BALF. Although
the results seem promising, one of the major limitations was
the rather small sample size. Future studies, in a lager
cohort of well-defined sarcoidosis patients, are necessary
to evaluate the clinical value of this observation. The
collection of well-defined sarcoidosis samples is time
consuming. Moreover, to establish the diagnostic value a
population of patients suffering from other interstitial
lung diseases should be included as well. Further attempts
will be undertaken, because the identification of these two
markers will lead to a better understanding of sarcoidosis
and would be of great interest. In future studies, we will
enlarge the sample group and we will also validate our
markers with a blind sample set. After this validation, we
can search for disease activity markers. Eventually, im-
plementation of a quantitative immunoassay, is needed, to
give a good prediction of the disease state and disease
severity.
In conclusion, the present study showed that protein
profiling in serum can be used in the management of
sarcoidosis. The peak of the multimarker at m/z 17,377 was
identified as the a-2 chain of haptoglobin.References
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